

**Waist Circumference as a potential indicator of cardiac autonomic profile in Metabolic Syndrome - A cross-sectional study.**

**Author and Affiliations -**

Name	Email ID	Affiliation
Dr. Ankith Bhasi	<a href="mailto:ankithbasee@gmail.com">ankithbasee@gmail.com</a>	Department of Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.
Dr. Oshin Puri	<a href="mailto:purioshin@gmail.com">purioshin@gmail.com</a>	MBBS Intern/MS5, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.
<b>Dr. Monika Pathania*</b>	<a href="mailto:ansupathania27@gmail.com">ansupathania27@gmail.com</a>	<b>Additional Professor, Department of Geriatric Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.</b>
Dr. Sarama Saha	<a href="mailto:saramasaha@yahoo.co.in">saramasaha@yahoo.co.in</a>	Associate Professor, Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.
Dr. Meenakshi Dhar	<a href="mailto:minakshi.dhar@rediffmail.com">minakshi.dhar@rediffmail.com</a>	Additional Professor and Head, Department of Geriatric Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.
Dr. Poorvi Kulshreshta	<a href="mailto:poorvi77@gmail.com">poorvi77@gmail.com</a>	Additional Professor, Department of Physiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand-249203, India.

\*Corresponding Author

**Running Title** - Waist Circumference and Autonomic Dysfunction in Metabolic Syndrome

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

**Abstract:**

*Introduction* - Metabolic Syndrome (MetS), a global epidemic on the rise, affects about one-third of the world's population. MetS poses significant cardiovascular risk often assessed through the cardiac autonomic function test Heart Rate Variability (HRV). This study attempts to identify a suitable anthropometric or biochemical proxy for resource-intensive HRV to assess cardiac autonomic profile in primary and community healthcare setups.

*Methodology* - This cross-section study assessed relevant anthropometric, biochemical, and HRV parameters of 174 patients recently diagnosed with MetS.

*Results* - Waist circumference (WC) had a significant ( $p < 0.05$ ) moderate to strong ( $r = 0.49$ ) positive correlation with sympathetic predominant HRV parameters - LFnu and LF/HF ratio. Parasympathetically modulated HRV parameters like Average RR ( $r = -0.17$ ), rMSSD ( $r = -0.23$ ), and HF ( $r = -0.49$ ) had a significant ( $p < 0.05$ ) negative correlation with WC.

*Conclusion* - The study identifies WC as a suitable indicator for cardiac autonomic profile in patients with MetS and by extension of cardiovascular posed by the disease.

**Keywords:** Metabolic Syndrome. Waist circumference, Heart Rate Variability, Obesity.

**Introduction-** The prevalence of Metabolic Syndrome (MetS) (as per the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III definition) among rural and urban Indian populations is 24.6% and 16.9% respectively. (1-3) Even such high numbers are surpassed by many other countries worldwide such as 49% in urban Pakistan, 37.1% in Malaysia, 35.8% in Australia, and 32.8% in Mongolia. (3-7) The International Diabetes Federation (IDF) and NCEP ATP III define MetS as a cluster of inter-connected metabolic abnormalities involving glucose and lipid metabolism, elevated blood pressure, and central obesity. (8) Insulin resistance, atherosclerotic cardiovascular diseases, a general pro-thrombotic and pro-inflammatory state, non-alcoholic steatohepatitis, and reproductive disorders are some of the many comorbidities associated with MetS. (3, 9-13)

Among many, the most well-established and concerning co-morbidity associated with MetS is its cardiovascular risk. Along with hypertension and dyslipidemia, which are components of the disease itself, MetS also creates a pro-thrombotic, pro-inflammatory internal environment and increases circulating reactive oxygen species, all contributing to increased cardiovascular risk among MetS patients. (11, 12, 14) These inter-dependent and co-existing metabolic derangements and the uncertainty of a causal relation between them pose a challenge to understanding cardiovascular risk of MetS. What is the cardiovascular risk size or proportion of elevated glucose, cholesterol, or blood pressure in the background of MetS? Is the cardiovascular risk posed by MetS a summation of the risk posed by its constituent pathological components? If not, is it less or more than the summation? and Why?

Such physiological and pathological systems are a challenge to understand in terms of mathematical summations or other formulations. Moreover, these parameters are evaluated using biochemicals with high time-to-time variability and can be controlled with medication. Once controlled over medication it is tough to establish the cardiovascular damage their derangements might have already done. In an attempt to simplify the complex interplay between MetS components and their resultant cardiovascular risk, Grassi G. et. al. hypothesized that sympathetic overdrive might be a common pathogenic background for all MetS derangements and the cardiovascular risk associated with it. (15)

There is enough evidence suggesting that sympathetic overdrive is associated with MetS as a whole and not just its component metabolic derangements. (16-18) Sympathetic overdrive contributes to the cardiovascular risk associated with MetS and might be a reliable indicator of the cumulative cardiovascular risk of the disease. (15, 19, 20) Cardiac (primarily left ventricular) hypertrophy, and abnormalities in arterial wall thickness, distensibility, and compliance have been demonstrated to stem from this hyperadrenergic pathogenic background of MetS. (15, 21-26) Hence, the autonomic profile especially the cardiac autonomic profile might be a suitable indicator of cardiovascular risk in MetS.

The activity of the autonomic nervous system can be evaluated through Autonomic Function Tests (AFTs) such as Heart Rate Variability (HRV), Blood Pressure Variability, Cold Pressor Test, Valsalva Maneuver, and Galvanic Skin Response to name a few. HRV is often referred to as a cardiac AFT (cAFT) since along with the general autonomic profile, it is a particularly accurate predictor of the autonomic regulation of the heart. (27) AFTs are resource-intensive diagnostics and the equipment as well as technically skilled manpower are seldom available at primary, community, or even district healthcare centers. Hence, even though it is reliable it might have limited practical use at a large scale.

We are curious if a biochemical or anthropometric measure has a significant correlation with the cardiac autonomic profile of MetS to be used as a suitable mass-scale proxy for cAFTs and by extension a determinant of cardiovascular risk. Thus, the current study assesses the correlation between cardiac autonomic function (namely HRV), and biochemical and anthropometric measures of patients with MetS in search of a reliable biochemical or anthropometric proxy for the cardiac autonomic function profile and by extension cardiovascular risk.

## **Methodology-**

**Study Design** - This study was conducted as a cross-sectional study.

**Consent and Ethical Considerations** - A written well-informed consent was taken from all participants. The study was conducted with due ethical clearance from the Institutional Ethics Committee (IEC). The study complies with the Declaration of Helsinki.

**Study Population** - The study was conducted with 174 adults (age > 18 years) who reported to a tertiary healthcare center's Lifestyle Disease Outpatient Clinic in Uttarakhand, India, and were diagnosed with MetS. Potential participants with liver disease, renal disorder (stage 4 and 5 CKD), hypothyroidism, and suffering from acute illnesses at the time of the study and known cases of MetS were excluded.

**Study Tools and Outcome Measures** -

*National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Definition of Metabolic Syndrome* - MetS suspects were diagnosed and hence approached for participation as per the NCEP ATP III definition with abdominal circumference corrected based on IDF criteria for Asians. (28, 29, Table-1)

<b>MetS Component</b>	<b>NCEP-ATP III (2001): 3 of the following 5 parameters.</b>
Abdominal Circumference (Modified as per IDF criteria for South Asian, Chinese, and Japanese populations).	Male: $\geq 90$ cm Female: $\geq 80$ cm
Triglyceride	$\geq 150$ mg/dl
HDL-C	Male: <40 mg/dL Female: <50 mg/dL
Blood Pressure	$\geq 130/85$ mmHg or hypertensive on treatment.
Fasting Blood Sugar	$\geq 100$ mg/dl or diabetic on treatment

***Table 1- NCEP ATP III Diagnostic definition of MetS***

*Biochemical, Anthropometric, and Electrophysiological Parameters -*

<b>Parameters</b>	<b>Equipment</b>	<b>Test</b>	<b>Outcome Measure</b>
<b>Blood Pressure</b>	Aneroid Sphygmomanometer	Auscultatory Blood Pressure Monitoring	mmHg
<b>Fasting Blood Glucose</b>	Beck man coulter AU480 auto analyzer	Hexokinase method	mg/dL
<b>Postprandial Blood Glucose</b>	Beck man coulter AU480 auto analyzer	Hexokinase method	mg/dL
<b>HbA1C</b>	Tosoh G8HPLC analyzer	Ion exchange High-performance liquid chromatography	%
<b>Waist Circumference</b>	Inch Tape		cm
<b>Serum TAG</b>	Beck man coulter AU480 auto analyzer	Colorimetric assay by coupled enzymatic reaction	mg/dL
<b>Serum HDL</b>	Beck man coulter AU480 auto analyzer	Colour-producing enzymatic reaction	mg/dL
<b>Serum LDL</b>	Beck man coulter AU480 auto analyzer	Immunoprecipitation followed by enzymatic cholesterol measurement	mg/dL
<b>Heart rate Variability</b>	Powerlab, AD Instruments	Electrocardiography	-

***Table 2- Biochemical, Anthropometric and Electrophysiological Parameters***

**Methodology** - Participants were invited for short-term (5-minute) ECG recordings for HRV evaluation. Patients were telephonically reminded about the appointment and advised to wear loose clothes for the appointment, and to avoid heavy meals, caffeine, or smoking, and have a good night's sleep one day prior. During the appointment, ECG leads were applied and the patients were rested for 20 minutes followed by short-term HRV testing.

**Statistical analysis:** The data were maintained in Microsoft Excel 2019 and analyzed in IBM-SPSS Version 23. For HRV, only time and frequency domain parameters were analyzed. Spearman Correlation was done to study the association between MetS components and HRV parameters. With a confidence level of 95%, a p-value of < 0.05 was taken to be significant.

**Results-** N=248 patients presented to the Internal Medicine Outpatient Department Lifestyle Disease Clinic were screened for MetS. Their anthropometric measures were recorded and routine blood investigations were sent. Of these, 174 individuals (n=87 males) were enrolled in the study. The descriptive statistics of metabolic syndrome components and HRV parameters among the study population are summarized in Table-3.

	<b>Mean</b>	<b>Std. Dev.</b>	<b>Median</b>	<b>25th Percentile</b>	<b>75th Percentile</b>	<b>IQR</b>
<b>Metabolic Syndrome Components</b>						
	<b>Mean</b>	<b>Std. Dev.</b>	<b>Median</b>	<b>25th Percentile</b>	<b>75th Percentile</b>	<b>IQR</b>
<b>SBP (mmHg)</b>	137.5287356	16.76035722	140	130	147.5	17.5
<b>DBP (mmHg)</b>	87.37931034	7.894157317	90	80.5	90	9.5
<b>FBS (mg/dL)</b>	113.3563218	38.78485999	103	98	112	14
<b>HbA1c (%)</b>	6.38545977	1.087175673	6.1	5.8025	6.6925	0.89

All rights reserved. No reuse allowed without permission.

<b>BMI (Kg/m<sup>2</sup>)</b>	31.17425287	3.344262495	30.2	29.125	32.0375	2.9125
<b>WC (cm) (Females)</b>	103.2988506	10.60398668	102	96.5	110	13.5
<b>WC (cm) (Males)</b>	100.3908046	6.0719644	100	96.5	104.5	8
<b>TG (mg/dL)</b>	169.0057471	24.7726068	167	155	180	25
<b>HDL (mg/dL) (Females)</b>	42.84827586	5.782408408	42	39	46.5	7.5
<b>HDL (mg/dL) (Males)</b>	42.10804598	5.754335441	41	38	45	7
<b>Heart Rate Variability (HRV) Parameters</b>						
	<b>Mean</b>	<b>Std. Dev.</b>	<b>Median</b>	<b>25th Percentile</b>	<b>75th Percentile</b>	<b>IQR</b>
<b>Average RR (ms)</b>	799.9442529	140.918009	787.6	709.45	882.725	173.275
<b>Median RR (ms)</b>	794.8739713	153.5833827	782.5	707.5	889	181.5
<b>SDRR (ms)</b>	31.47013793	21.12279575	25.835	15.77	42.6775	26.9075
<b>Average Heart Rate (bpm)</b>	76.58937931	15.70840235	76.29	67.8	84.445	16.645
<b>rMSSD (ms)</b>	23.08928333	20.65724914	15.455	9.652	30.9575	21.3055
<b>VLF (ms<sup>2</sup>)</b>	626.4992989	940.8246598	278.4	98.9675	751.825	652.8575
<b>LF (ms<sup>2</sup>)</b>	450.8279121	842.4066306	141.5	48.765	524.95	476.185
<b>LFnu</b>	56.43261494	21.80142609	57.57	40.085	74.6175	34.5325
<b>HF (ms<sup>2</sup>)</b>	381.1159885	907.632661	98.305	34.73	375.8369914	341.1069914
<b>HFnu</b>	42.82266092	20.33947361	42.415	25.865	58.525	32.66
<b>LF/HF Ratio</b>	2.258923908	2.578158525	1.4075	0.6817	2.855	2.1733
<b>SD1</b>	16.35138046	14.63794815	10.945	6.833	21.9225	15.0895
<b>SD2</b>	41.07145402	26.8478233	34	21.3275	53.615	32.2875



All rights reserved. No reuse allowed without permission.

\*\*SBP - Systolic Blood Pressure, DBP- Diastolic Blood Pressure, FBS - Fasting Blood Sugar, HbA1C - Glycated Hemoglobin, BMI - Body-Mass Index, WC- Waist Circumference TAG - Triacylglycerol, HDL - High-Density Lipoprotein, RR - RR Interval, SDRR - Standard Deviation of RR Interval, VLF - Very Low Frequency, LF - Low Frequency, HF - High Frequency



**Table-3 - MetS components and HRV parameters of Metabolic Syndrome patients included in the study.**


The anthropometric and biochemical parameters were then tested for any significant correlation with HRV parameters as shown in Table-4.

	<b>SBP</b>	<b>DBP</b>	<b>WC</b>	<b>FBS</b>	<b>TG</b>	<b>HDL</b>
<b>AVG HR</b>	0.030 (0.74)	0.030 (0.67)	-0.01 (0.93)	0.12 (0.13)	0.12 (0.129)	0.090 (0.21)
<b>AVG RR</b>	-0.02 (0.77)	-0.03 (0.65)	<b>-0.17</b> <b>(0.02)</b>	0.03 0.65	-0.09 (0.22)	-0.1 (0.18)
<b>SDRR</b>	0.02 (0.79)	0 (0.96)	-0.08 (0.28)	0.09 (0.24)	-0.07 (0.34)	0.08 0.314
<b>rMSSD</b>	-0.05 (0.520)	-0.03 (0.702)	<b>-0.23</b> <b>(0.002)</b>	0.08 (0.319)	-0.06 (0.400)	0.05 (0.49)
<b>VLF</b>	0.09 (0.221)	0.07 (0.385)	-0.04 (0.597)	0.02 (0.806)	-0.11 (0.159)	0.07 (0.376)
<b>LF</b>	0 (0.955)	-0.03 (0.721)	0.03 (0.704)	0.02 (0.841)	-0.02 (0.804)	0.1 (0.184)
<b>LFnu</b>	0.04 (0.559)	-0.05 (0.492)	<b>0.49</b> <b>&lt;0.001</b>	0.02 (0.843)	0.15 (0.53)	0.1 (0.188)
<b>HF</b>	-0.04 (0.596)	-0.05 (0.475)	<b>-0.22</b> <b>(0.003)</b>	0.04 (0.562)	-0.08 (0.284)	0.04 (0.557)
<b>HFnu</b>	-0.05 (0.555)	0.05 (0.539)	<b>-0.49</b> <b>&lt;0.001</b>	-0.01 (0.896)	-0.15 (0.051)	-0.11 (0.162)
<b>LF/HF</b>	0.04 (0.622)	-0.05 (0.494)	<b>0.49</b> <b>&lt;0.001</b>	0.02 (0.82)	<b>0.15</b> <b>(0.048)</b>	0.11 (0.165)


***Table-4 - Spearman test between MetS components and HRV parameters.***

Waist circumference (WC) was reported to have a significant moderate to strong positive correlation with sympathetic predominant HRV parameters - LFnu and LF/HF ratio. (Table-4) Parasympathetically modulated HRV parameters like Average RR, rMSSD, and HF had a negative correlation with WC. (Table-4). No other biochemical or anthropometric measure shows a consistent correlation to autonomic parameters. (Table-4) The significant correlations have been described in greater detail in Table-5.


Scatter Plot	Description
	<p>Weak positive statistically significant (<math>\rho = 0.21</math>, <math>p = 0.006</math>) correlation between WC (cm) and Average Heart Rate (bpm). A 1 unit increase in WC (cm), was associated with 0.40 unit increase in the average heart rate (bpm). On the other side, a 1 unit increase in average heart rate (bpm), was associated with 0.13 unit increase in WC.</p>
	<p>A negative statistically significant (<math>\rho = -0.18</math>, <math>p = 0.018</math>) correlation between WC (cm) and Average RR (ms). A 1-unit increase in WC (cm), was associated with a 2.94-unit decrease in the average RR (ms). On the other side, a 1 unit increase in average RR (ms), was associated with a 0.01 unit decrease in the WC (cm).</p>





A weak negative statistically significant ( $\rho = -0.23$ ,  $p = 0.002$ ) correlation between WC (cm) and rMSSD (ms). A 1 unit increase in WC (cm), was associated with a decrease of rMSSD (ms) by 0.47 units. On the other side, a 1 unit increase in rMSSD (ms), was associated with a 0.08 unit decrease in WC (cm).



A moderate positive statistically significant ( $\rho = 0.48$ ,  $p = <0.001$ ) correlation between WC (cm) and LFnu. A 1 unit increase in WC (cm), was associated with an increase of LFnu by 1.10 units. On the other side, a 1 unit increase in LFnu was associated with a 0.18 unit increase in WC.



A weak negative statistically significant ( $\rho = -0.22$ ,  $p = 0.003$ ) correlation between WC (cm) and HF (ms<sup>2</sup>). A 1 unit increase in WC (cm), was associated with a 14.24 unit decrease in the HF (ms<sup>2</sup>). On the other side a 1 unit increase in HF (ms<sup>2</sup>), was associated with a 0.00 decrease in WC (cm).

	<p>A moderate negative statistically significant (<math>\rho = -0.48</math>, <math>p = &lt;0.001</math>) correlation between WC (cm) and HFnu. A 1 unit increase in WC (cm), was associated with a 1.01 unit decrease in HFnu. On the other side a 1 unit increase in HFnu, was associated with a 0.19 unit decrease in WC (cm).</p>
	<p>A moderate positive statistically significant (<math>\rho = 0.48</math>, <math>p = &lt;0.001</math>) correlation between WC (cm) and LF/HF Ratio. A 1 unit increase in WC (cm), was associated with a 0.11 unit increase in the LF/HF ratio. On the other side a 1 unit increase in LH/HF ratio, was associated with a 1.21 unit increase in the WC (cm).</p>

***Table-5 - Scatter plots depicting significant correlations between Autonomic parameters, and waist circumference.***

**Discussion-** HRV is a validated cAFT known to record the general and especially the cardiac autonomic profile accurately. (27) While, it is considered ideal to have a 24-hour ECG recording for accurate evaluation of HRV, short-term (5-minute) ECG recordings, have long been a convenient tool to reliably study cardiac autonomic function. (27) ECG can be analyzed to generate time-domain, frequency-domain, and non-linear measurements. Time-domain HRV parameters are Avg HR, Avg RR, SDRR, SDANN, SDNN Index, RMSSD, NN50, and pNN50 of which Avg HR, Avg RR, SDRR, and RMSSD were analyzed in the current study. Of the frequency-domain parameters, VLF, LF, and HF frequency parameters were analyzed. Among

the analyzed parameters, RMSSD, and HF nu are well-known indicators of parasympathetic activity, and LF nu and LF/HF ratio, of sympathetic activity. (27)

In Shaffer F. et. al.'s words, the autonomic nervous system must not be understood as a “zero-sum” combination of sympathetic and parasympathetic nervous activity. (27) Hence, it is ideal to discuss the sympathetic and parasympathetic nervous activity separately. The primary autonomic derangement reported in MetS is a general sympathetic overdrive. (15, 30-32) Evidence from a variety of experiments and studies has been reporting the same for over a decade. (30, 31) This sympathetic overdrive at the level of the heart plays a pathogenic role in cardiovascular comorbidities associated with MetS. (15) The profile of parasympathetic activity still has scope to be better understood, although studies have reported a loss of recovery of heart rate after a stressful situation, (a cardiac parasympathetic function) to be impaired in the setting of MetS. (33, 34) In toto, cardiac sympathetic activity increases while cardiac parasympathetic activity decreases in the setting of MetS and poses a cardiovascular risk.

Several attempts have been made to quantify these cardiac autonomic imbalances in MetS through cAFTs, and hence predict cardiovascular risk based on these results. HRV parameters reported to be significantly deranged in MetS are rMSSD, LF power, HF power, and LF/HF ratio. (35-39) The cardiac sympathetic overdrive in the setting of MetS manifests as an elevated LF power/LF nu and a high LF/HF ratio. (35-39). The HF power/HF nu has been reported to decrease in MetS. (36-39) These findings pose a cardiovascular risk in several pathogenic backgrounds including MetS over the long term.

These findings from the literature enable us to streamline our approach toward identifying an anthropometric or biochemical proxy for the cardiac autonomic profile in MetS. A given biochemical or anthropometric parameter having moderate to strong statistically significant correlation with the HF, LF, and LF/HF ratio might be a suitable proxy. In the current study, only WC showed a significant ( $p < 0.05$ ) moderate ( $r = 0.49$ ) correlation with LF nu, HF nu, and LF/HF ratio. The nature of the correlation of WC with LF nu and LF/HF ratio was positive while that with HF nu was negative. This suggests that WC might be used as a proxy for the cardiac autonomic profile in the setting of MetS.

Similar to our study, a recent study from Southern India analyzed the correlation between anthropometric/biochemical parameters and cardiac autonomic function among pre-MetS patients and reported a significant but weak correlation between abdominal obesity or waist-hip ratio, and LF/HF ratio. (37) A meta-analysis summarising data published until 2014 reported a strong correlation between WC and cardiac autonomic function parameters. (40) It further emphasizes this correlation to be stronger than association with any other anthropometric or biochemical parameter. (40) Original work led by the same author in the following year also reported WC to be most commonly associated with HRV (41) A meta-analysis studying similar objectives among the pediatric population reported a significant correlation between WC and LF/HF ratio and HF nu after an analysis of 3,000+ patients each. (42) These results can form the basis for validation of WC as an indicator of cardiac autonomic profile in MetS in rural and resource-limited healthcare setups. While HRV analysis requires an ECG machine, algorithms/software in place to analyze HRV, and trained medical staff to understand and interpret the results, WC can be measured using an inch tape available in every household. Moreover, it does not require much technical expertise in analyzing or interpreting it. Although a parameter like WC is more likely to vary across populations and cultures, thus it requires significant effort to establish valid cut-offs especially if it is to be used as an indicator of cardiac autonomic profile. Hence, WC might be a measure with significant practical application in primary and community healthcare.

It is worth noting that, WC has been the representative anthropometric measure of abdominal obesity and visceral adiposity for decades. The expanding understanding of the etiopathogenesis of MetS has led to the conclusion that of the four diagnostic components of MetS, the causative role of visceral adiposity is the most well-established. (43) Visceral adiposity has been shown to trigger most pathways of MetS. (43-45) Moreover, adipose hypertrophy even in the absence of confounding insulin resistance or Type-2 Diabetes Mellitus, atherosclerotic cardiovascular disease, smoking, macro-inflammation, or lipid therapy has been shown to be associated with MetS. (46) Visceral adiposity increases the supply of free fatty acids, especially in the splanchnic circulation, and hence to the liver in turn contributing to insulin resistance. (43, 47) Insulin resistance underlies the remaining three diagnostic components of MetS - elevated blood glucose, dyslipidemia, and hypertension at least partly. (43, 48) This hypothesis of visceral adiposity being the

induction point of MetS provides a logical explanation behind WC being a suitable indicator of cardiac autonomic function. Since visceral adiposity is present at the scene of crime since (or maybe even before) the precipitation of MetS, its anthropometric indicator (WC), and complication (namely cardiac autonomic imbalance) are likely to be correlated in the disease setting.

The meta-analysis from 2014 reported an inconsistent relation between cardiac autonomic function and blood pressure as well. (40) The associations were significant among children but not among adults. (40) Just like blood pressure, inconsistent associations were also reported between cardiac autonomic function and fasting plasma glucose, and triglycerides. (40) Contrary to the current study, there are reports of hyperglycemia also being a reliable predictor of cardiac autonomic function. (49, 50) The meta-analysis of the pediatric population reported different cardiac autonomic parameters to have significant correlations with SBP, DBP, WC, TAGs, and HDL. (42) There is a major inconsistency in the literature related to correlations between cardiac autonomic function and MetS parameters. A number of hypotheses can be postulated to understand the difference between the findings of the current study and those published in the literature. The vast pathophysiological background of metabolic syndrome creates scope for anthropometric and biochemical parameters of the disease to be affected by an even larger number of variations in diet, lifestyle, and day-to-day stress to name a few. These factors definitely differ between individuals and even more significantly between populations. Similarly, inherited and acquired genetic mutations may also play a role in the same disease expressing a different biochemical or anthropometric phenotype. Such variation may amount to the inconsistency discussed above.

Hence, it is safe to say that the current study identifies WC as a potential indicator of cardiac autonomic profile in MetS most reliably for residents of western Uttar Pradesh and Uttarakhand. It also emphasizes the need for center-focused studies to identify population-specific proxies for diagnostics like HRV to facilitate public and community healthcare.

Validation of population-specific WC cut-offs and WC-based risk stratification by employing alternate tools might be the steps ahead to understand the relation between WC and cardiac autonomic function or cardiovascular risk. A longitudinal study following up the biochemical and anthropometric measures of

patients throughout the course of the disease might give us more information. Also, a better lifestyle, socio-cultural, and genetic profiling of MetS patients might reveal different phenotypic variations of the disease and hence yield information on the correlative incongruity identified in the existing literature.

**Conclusions-** The study identifies WC as a suitable indicator for cardiac autonomic profile in patients with MetS and by extension of cardiovascular posed by the disease. WC is of particular use for a country with limited healthcare resources and hence must be further probed into for its mass-scale practical applications.

**Conflict of Interest:** The authors do not have any conflict of interest to declare.

**External Funding:** The study was conducted at All India Institute of Medical Sciences (AIIMS), Rishikesh, Uttarakhand, India. No external funding was applied for or received for the conduction of this study.

## **References-**

1. Chow, C. K., Naidu, S., Raju, K., Raju, R., Joshi, R., Sullivan, D., Celermajer, D. S., & Neal, B. C. (2008). Significant lipid, adiposity, and metabolic abnormalities amongst 4535 Indians from a developing region of rural Andhra Pradesh. *Atherosclerosis*, *196*(2), 943–952. <https://doi.org/10.1016/j.atherosclerosis.2007.02.027>
2. Ravikiran, M., Bhansali, A., Ravikumar, P., Bhansali, S., Dutta, P., Thakur, J. S., Sachdeva, N., Bhadada, S., & Walia, R. (2010). Prevalence and risk factors of metabolic syndrome among Asian Indians: a community survey. *Diabetes research and clinical practice*, *89*(2), 181–188. <https://doi.org/10.1016/j.diabres.2010.03.010>
3. Ranasinghe, P., Mathangasinghe, Y., Jayawardena, R., Hills, A. P., & Misra, A. (2017). Prevalence and trends of metabolic syndrome among adults in the Asia-Pacific region: a systematic review. *BMC Public Health*, *17*(1), 101. <https://doi.org/10.1186/s12889-017-4041-1>
4. Vaughan, C., Schoo, A., Janus, E. D., Philpot, B., Davis-Lameloise, N., Lo, S. K., Laatikainen, T., Vartiainen, E., & Dunbar, J. A. (2009). The association of levels of physical activity with metabolic



syndrome in rural Australian adults. *BMC Public Health*, 9, 273.

<https://doi.org/10.1186/1471-2458-9-273>

5. Mohamud, W. N., Ismail, A. A., Sharifuddin, A., Ismail, I. S., Musa, K. I., Kadir, K. A., Kamaruddin, N. A., Yaacob, N. A., Mustafa, N., Ali, O., Harnida, S., & Bebakar, W. M. (2011). Prevalence of metabolic syndrome and its risk factors in adult Malaysians: results of a nationwide survey. *Diabetes research and clinical practice*, 91(2), 239–245. <https://doi.org/10.1016/j.diabres.2010.11.025>
6. Enkh-Oyun, T., Kotani, K., Davaalkham, D., Davaa, G., Ganchimeg, U., Angarmurun, D., Khuderchuluun, N., Batzorig, B., Tsuboi, S., Ae, R., Aoyama, Y., & Nakamura, Y. (2015). Epidemiologic features of metabolic syndrome in a general Mongolian population. *Metabolic syndrome and related disorders*, 13(4), 179–186. <https://doi.org/10.1089/met.2014.0067>
7. Hydrie, M. Z., Shera, A. S., Fawwad, A., Basit, A., & Hussain, A. (2009). Prevalence of metabolic syndrome in urban Pakistan (Karachi): comparison of newly proposed International Diabetes Federation and modified Adult Treatment Panel III criteria. *Metabolic syndrome and related disorders*, 7(2), 119–124. <https://doi.org/10.1089/met.2008.0055>
8. Amihăesei, I. C., & Chelaru, L. (2014). Metabolic syndrome a widespread threatening condition; risk factors, diagnostic criteria, therapeutic options, prevention and controversies: an overview. *Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi*, 118(4), 896–900.
9. Cornier, M. A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008). The metabolic syndrome. *Endocrine Reviews*, 29(7), 777–822. <https://doi.org/10.1210/er.2008-0024>
10. O'Neill, S., & O'Driscoll, L. (2015). Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. *Obesity reviews: an official journal of the International Association for the Study of Obesity*, 16(1), 1–12. <https://doi.org/10.1111/obr.12229>
11. Grundy, S. M., Cleman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., Jr, Spertus, J. A., Costa, F., American Heart Association, & National Heart, Lung, and Blood Institute (2005). Diagnosis and management of the

metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute

Scientific Statement. *Circulation*, 112(17), 2735–2752.

<https://doi.org/10.1161/CIRCULATIONAHA.105.169404>

12. Wilson, P. W., D'Agostino, R. B., Parise, H., Sullivan, L., & Meigs, J. B. (2005). Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation*, 112(20), 3066–3072. <https://doi.org/10.1161/CIRCULATIONAHA.105.539528>
13. Vykoukal, D., & Davies, M. G. (2011). Vascular biology of metabolic syndrome. *Journal of Vascular Surgery*, 54(3), 819–831. <https://doi.org/10.1016/j.jvs.2011.01.003>
14. Silveira Rossi, J. L., Barbalho, S. M., Reverete de Araujo, R., Bechara, M. D., Sloan, K. P., & Sloan, L. A. (2022). Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. *Diabetes/metabolism research and reviews*, 38(3), e3502. <https://doi.org/10.1002/dmrr.3502>
15. Grassi, G., Quarti-Trevano, F., Seravalle, G., & Dell'Oro, R. (2007). Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. *Nutrition, metabolism, and cardiovascular diseases: NMCD*, 17(6), 473–481. <https://doi.org/10.1016/j.numecd.2007.01.004>
16. Esler, M., Straznicky, N., Eikelis, N., Masuo, K., Lambert, G., & Lambert, E. (2006). Mechanisms of sympathetic activation in obesity-related hypertension. *Hypertension (Dallas, Tex. : 1979)*, 48(5), 787–796. <https://doi.org/10.1161/01.HYP.0000242642.42177.49>
17. Huggett, R. J., Burns, J., Mackintosh, A. F., & Mary, D. A. (2004). Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. *Hypertension (Dallas, Tex. : 1979)*, 44(6), 847–852. <https://doi.org/10.1161/01.HYP.0000147893.08533.d8>
18. Clark M. G. (2005). Comment to: Grassi G, Dell'oro R, Quarti-Trevano F et al (2005) neuro adrenergic and reflex abnormalities in patients with metabolic syndrome. *Diabetologia* 48:1359-1365. *Diabetologia*, 48(12), 2689–2690. <https://doi.org/10.1007/s00125-005-0012-7>
19. Endukuru, C. K., Gaur, G. S., Yerrabelli, D., Sahoo, J., & Vairappan, B. (2020). Impaired baroreflex sensitivity and cardiac autonomic functions are associated with cardiovascular disease risk factors among patients with metabolic syndrome in a tertiary care teaching hospital in South India. *Diabetes & metabolic syndrome*, 14(6), 2043–2051. <https://doi.org/10.1016/j.dsx.2020.10.018>

20. Grassi G. (2006). Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. *Hypertension research: Official journal of the Japanese Society of Hypertension*, 29(11), 839–847. <https://doi.org/10.1291/hypres.29.839>
21. Chinali, M., Devereux, R. B., Howard, B. V., Roman, M. J., Bella, J. N., Liu, J. E., Resnick, H. E., Lee, E. T., Best, L. G., & de Simone, G. (2004). Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). *The American journal of cardiology*, 93(1), 40–44. <https://doi.org/10.1016/j.amjcard.2003.09.009>
22. de Simone G. (2005). State of the heart in the metabolic syndrome. *Nutrition, metabolism, and cardiovascular diseases: NMCD*, 15(4), 239–241. <https://doi.org/10.1016/j.numecd.2005.06.006>
23. Devereux, R. B., de Simone, G., Palmieri, V., Oberman, A., Hopkins, P., Kitzman, D. W., Rao, D. C., & Arnett, D. K. (2002). Relation of insulin to left ventricular geometry and function in African American and white hypertensive adults: the HyperGEN study. *American journal of hypertension*, 15(12), 1029–1035. [https://doi.org/10.1016/s0895-7061\(02\)03080-7](https://doi.org/10.1016/s0895-7061(02)03080-7)
24. Burchfiel, C. M., Skelton, T. N., Andrew, M. E., Garrison, R. J., Arnett, D. K., Jones, D. W., & Taylor, H. A., Jr. (2005). Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*, 112(6), 819–827. <https://doi.org/10.1161/CIRCULATIONAHA.104.518498>
25. Scuteri, A., Najjar, S. S., Muller, D. C., Andres, R., Hougaku, H., Metter, E. J., & Lakatta, E. G. (2004). Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. *Journal of the American College of Cardiology*, 43(8), 1388–1395. <https://doi.org/10.1016/j.jacc.2003.10.061>
26. Mulè, G., Cottone, S., Mongiovi, R., Cusimano, P., Mezzatesta, G., Seddio, G., Volpe, V., Nardi, E., Andronico, G., Piazza, G., & Cerasola, G. (2006). Influence of the metabolic syndrome on aortic stiffness in never-treated hypertensive patients. *Nutrition, metabolism, and cardiovascular diseases: NMCD*, 16(1), 54–59. <https://doi.org/10.1016/j.numecd.2005.03.005>
27. Shaffer, F., & Ginsberg, J. P. (2017). An Overview of Heart Rate Variability Metrics and Norms. *Frontiers in public health*, 5, 258. <https://doi.org/10.3389/fpubh.2017.00258>

28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*, 285(19), 2486–2497. <https://doi.org/10.1001/jama.285.19.2486>
29. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome, Available from - <http://www.idf.org/metabolic-syndrome>
30. Reaven, G. M., Lithell, H., & Landsberg, L. (1996). Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. *The New England journal of medicine*, 334(6), 374–381. <https://doi.org/10.1056/NEJM199602083340607>
31. Landsberg L. (1986). Diet, obesity, and hypertension: a hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. *The Quarterly journal of medicine*, 61(236), 1081–1090.
32. Thorp, A. A., & Schlaich, M. P. (2015). Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. *Journal of diabetes research*, 2015, 341583. <https://doi.org/10.1155/2015/341583>
33. Deniz, F., Katircibasi, M. T., Pamukcu, B., Binici, S., & Sanisoglu, S. Y. (2007). Association of metabolic syndrome with impaired heart rate recovery and low exercise capacity in young male adults. *Clinical endocrinology*, 66(2), 218–223. <https://doi.org/10.1111/j.1365-2265.2006.02711.x>
34. Kim, M. K., Tanaka, K., Kim, M. J., Matsuo, T., & Ajisaka, R. (2009). Exercise training-induced changes in heart rate recovery in obese men with metabolic syndrome. *Metabolic syndrome and related disorders*, 7(5), 469–476. <https://doi.org/10.1089/met.2008.0086>
35. Emdin, M., Gastaldelli, A., Muscelli, E., Macerata, A., Natali, A., Camastra, S., & Ferrannini, E. (2001). Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. *Circulation*, 103(4), 513–519. <https://doi.org/10.1161/01.cir.103.4.513>
36. Kangas, P., Tikkakoski, A., Uitto, M., Viik, J., Bouquin, H., Niemelä, O., Mustonen, J., & Pörsti, I. (2019). Metabolic syndrome is associated with decreased heart rate variability in a sex-dependent

- manner: a comparison between 252 men and 249 women. *Clinical physiology and functional imaging*, 39(2), 160–167. <https://doi.org/10.1111/cpf.12551>
37. Kumar, E. C., Gaur, G. S., Yerrabelli, D., Sahoo, J., Vairappan, B., & Goud, A. C. (2023). Association between metabolic syndrome components and cardiac autonomic modulation in southern Indian adults with pre-metabolic syndrome: hyperglycemia is the major contributing factor. *The Korean journal of physiology & pharmacology: official journal of the Korean Physiological Society and the Korean Society of Pharmacology*, 27(1), 49–59. <https://doi.org/10.4196/kjpp.2023.27.1.49>
38. Wulsin, L. R., Horn, P. S., Perry, J. L., Massaro, J. M., & D'Agostino, R. B., Sr (2016). The Contribution of Autonomic Imbalance to the Development of Metabolic Syndrome. *Psychosomatic medicine*, 78(4), 474–480. <https://doi.org/10.1097/PSY.0000000000000290>
39. Keerthi, G. S., Pal, P., Pal, G. K., Sahoo, J. P., Sridhar, M. G., & Balachander, J. (2016). Attenuated baroreflex sensitivity in normotensive prediabetes and diabetes in Indian adults. *Endocrine Research*, 41(2), 89–97. <https://doi.org/10.3109/07435800.2015.1076454>
40. Stuckey, M. I., Tulppo, M. P., Kiviniemi, A. M., & Petrella, R. J. (2014). Heart rate variability and the metabolic syndrome: a systematic review of the literature. *Diabetes/metabolism research and reviews*, 30(8), 784–793. <https://doi.org/10.1002/dmrr.2555>
41. Stuckey, M. I., Kiviniemi, A., Gill, D. P., Shoemaker, J. K., & Petrella, R. J. (2015). Associations between heart rate variability, metabolic syndrome risk factors, and insulin resistance. *Applied physiology, nutrition, and metabolism = Physiologie applique, nutrition et metabolisme*, 40(7), 734–740. <https://doi.org/10.1139/apnm-2014-0528>
42. Chang, Y. W., Lin, J. D., Chen, W. L., Yen, C. F., Loh, C. H., Fang, W. H., & Wu, L. W. (2012). Metabolic syndrome and short-term heart rate variability in adults with intellectual disabilities. *Research in developmental disabilities*, 33(6), 1701–1707. <https://doi.org/10.1016/j.ridd.2012.04.005>
43. Soares-Miranda, L., Sandercock, G., Vale, S., Santos, R., Abreu, S., Moreira, C., & Mota, J. (2012). Metabolic syndrome, physical activity and cardiac autonomic function. *Diabetes/metabolism research and reviews*, 28(4), 363–369. <https://doi.org/10.1002/dmrr.2281>

44. Supriya, R., Li, F. F., Yang, Y. D., Liang, W., & Baker, J. S. (2021). Association between Metabolic Syndrome Components and Cardiac Autonomic Modulation among Children and Adolescents: A Systematic Review and Meta-Analysis. *Biology*, *10*(8), 699. <https://doi.org/10.3390/biology10080699>
45. Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022). Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. *International journal of molecular sciences*, *23*(2), 786. <https://doi.org/10.3390/ijms23020786>
46. Matsuzawa, Y., Funahashi, T., & Nakamura, T. (2011). The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. *Journal of atherosclerosis and thrombosis*, *18*(8), 629–639. <https://doi.org/10.5551/jat.7922>
47. Pekgor, S., Duran, C., Berberoglu, U., & Eryilmaz, M. A. (2019). The Role of Visceral Adiposity Index Levels in Predicting the Presence of Metabolic Syndrome and Insulin Resistance in Overweight and Obese Patients. *Metabolic syndrome and related disorders*, *17*(5), 296–302. <https://doi.org/10.1089/met.2019.0005>
48. Jialal, I., Adams-Huet, B., & Devaraj, S. (2023). Increased Adipocyte Hypertrophy in Patients with Nascent Metabolic Syndrome. *Journal of Clinical Medicine*, *12*(13), 4247. <https://doi.org/10.3390/jcm12134247>
49. Patel, P., & Abate, N. (2013). Body fat distribution and insulin resistance. *Nutrients*, *5*(6), 2019–2027. <https://doi.org/10.3390/nu5062019>
50. Tripathy, D., Mohanty, P., Dhindsa, S., Syed, T., Ghanim, H., Aljada, A., & Dandona, P. (2003). Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. *Diabetes*, *52*(12), 2882–2887. <https://doi.org/10.2337/diabetes.52.12.2882>
51. Rasic-Milutinovic, Z. R., Milicevic, D. R., Milovanovic, B. D., Perunicic-Pekovic, G. B., & Pencic, B. D. (2010). Do components of metabolic syndrome contribute to cardiac autonomic neuropathy in non-diabetic patients? *Saudi Medical Journal*, *31*(6), 650–657.
52. Balcıoğlu, A. S., Akıncı, S., Çiçek, D., Çoner, A., Bal, U. A., & Müderrisoğlu, İ. H. (2016). Cardiac autonomic nervous dysfunction detected by both heart rate variability and heart rate turbulence in

prediabetic patients with isolated impaired fasting glucose. *Anatolian journal of cardiology*, 16(10),

762–769. <https://doi.org/10.14744/AnatolJCardiol.2015.6654>